Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * ≥ 18 and ≤ 75 years of age , with ≥ 40 Kg * Histological or cytological confirmed metastatic colorectal cancer * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Failed 2 or more lines of chemotherapy * Adequate hepatic, renal, heart, and hematologic functions * At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan) * Signed and dated informed consent. * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure Exclusion Criteria: * Pregnant or lactating women * Any factors that influence the usage of oral administration * Central nervous system (CNS) metastasis * One of the following conditions: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure * Abuse of alcohol or drugs * Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR inhibition * Disability of serious uncontrolled intercurrence infection * Proteinuria ≥ 2+ (1.0g/24hr) * Evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness * History of artery/venous thromboembolic events in 12 months, such as cerebral vascular accident (including transient ischemic attack) etc. * History of acute myocardial infarction, acute coronary syndrome or coronary artery bypass graft (CABG) in 6 months * Bone fracture or wounds that was not cured for a long time * Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy